FDA Strengthens Safety Label Warnings for Fluoroquinolone Antibiotics
The Food and Drug Administration yesterday announced safety labeling changes for fluoroquinolone antibiotics to strengthen warnings about the risk of mental health side effects and serious blood sugar disturbances. Based on a recent FDA review of adverse event reports and the medical literature, the updated labeling will highlight mental health side effects including disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium, and the potential risk of coma with hypoglycemia. Fluoroquinolone antibiotics are used to treat certain serious bacterial infections.
Related News Articles
Headline
A multistate cyclospora outbreak linked to iceberg lettuce has been declared over, the Centers for Disease Control and Prevention and Food and Drug…
Perspective
Twenty-five years ago, our nation experienced one of the darkest days in its history. The terrorist attacks of Sept. 11, 2001, took thousands of innocent lives…
Headline
The Federal Office of Rural Health Policy’s Rural Health Redesign Center will host a webinar on Sept. 24 at 2 p.m. ET, where hospital CEOs will discuss the…
Headline
Two individuals have died in Michigan in connection to the current multistate cyclosporiasis outbreak, the Michigan Department of Health and Human Services…
Headline
The AHA’s Living Learning Network, in partnership with the Centers for Disease Control and Prevention, July 22 released “Rural Sepsis Care in Action: Real-…
Headline
The Centers for Disease Control and Prevention July 14 released an advisory on the growing cyclosporiasis cases across the U.S. The advisory said that the…